WO2003105800A2 - Filmförmige mucoadhäsive darreichungsformen zur verabreichung von cannabis-wirkstoffen - Google Patents
Filmförmige mucoadhäsive darreichungsformen zur verabreichung von cannabis-wirkstoffen Download PDFInfo
- Publication number
- WO2003105800A2 WO2003105800A2 PCT/EP2003/004807 EP0304807W WO03105800A2 WO 2003105800 A2 WO2003105800 A2 WO 2003105800A2 EP 0304807 W EP0304807 W EP 0304807W WO 03105800 A2 WO03105800 A2 WO 03105800A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- form according
- cellulose
- cannabis
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Definitions
- Film-like mucoadhesive dosage forms for the administration of cannabxs active ingredients are provided.
- the present invention relates to film-like, mucoadhesive dosage forms which contain cannabis active ingredients and are suitable for the administration of cannabis active ingredients for therapeutic purposes.
- the invention further extends to the use of the dosage forms mentioned for the treatment of disease states in humans or animals.
- the ingredients of the Indian hemp plant (Cannabis sativa L.) have a variety of pharmacological effects, of which the psychotropic effect is best known.
- cannabis ingredients also have anti-emetic, anti-convulsive, muscle relaxant, analgesic, sedative, and appetite-increasing effects.
- cannabis ingredients with good efficacy can be used to treat insomnia, neuralgia, painful rheumatism and gastrointestinal disorders.
- a beneficial therapeutic effect of cannabis active ingredients has also been observed in the following indications:
- Painful conditions in cancer and as a result of chemotherapy Pain and wasting syndrome in AIDS; Nausea and vomiting as a side effect of chemotherapy, as well as with AIDS or hepatitis; Neuropathic pain; Anorexia or cachexia, especially in the case of AIDS or advanced cancer; Paralysis in multiple sclerosis or traumatic cross-sectional diseases; Dystonic movement disorders; Bronchial asthma; epileptic seizures or generalized epilepsy; Withdrawal symptoms with alcohol, benzodiazepine and opiate addiction; Parkinson disease; Dementia diseases, in particular Alzheimer's disease; Nausea; Arthritis; Glaucoma; Migraine; Dysmenorrhea.
- cannabis extracts and cannabis oils for therapeutic treatment purposes can also be considered. It is usually administered orally, e.g. in the form of capsules.
- Cannabis extracts or oils contain as pharmacologically active ingredients tetrahydrocannabinol (predominantly ⁇ -9-tetrahydro-cannabinol, to a lesser extent: ⁇ -8-tetrahydrocannabinol), cannabidiol, cannabinol and cannabichromes. These active ingredients are also referred to as cannabinoids (see overview "The Merck Index", 12th edition, 1996, p.285, No. 1794, and S.1573, No. 9349).
- This object is achieved by a film-like, mucoadhesive dosage form containing at least one active ingredient from the group of cannabis active ingredients according to claim 1; further preferred embodiments are described in the subclaims.
- the object is further achieved by using the film-like, mucoadhesive dosage forms according to the invention in the treatment of diseases or disease symptoms.
- the dosage forms according to the invention are applied to the oral mucosa, preferably in the form of thin sheets or wafer-shaped structures, where they remain adherent due to their mucoadhesive properties.
- the application on the oral mucosa is preferably sublingual or buccal.
- other mucosal surfaces can also be considered as the application site, e.g. B. the nasal mucosa.
- the cannabis active ingredient (s) contained in the dosage form is / are released to the surrounding saliva and subsequently resorbed by the oral mucosa (i.e. transmucosal).
- the active ingredient can also be released directly from the dosage form to the mucous membrane.
- the dosage form absorbs saliva and the active ingredient it contains is diffused to the outside.
- the active substance is released into the saliva after a very short delay, so that the saliva-active substance mixture can immediately reach all areas of the oral mucosa and be resorbed there.
- the amount of saliva in which the released active ingredient is dissolved or dispersed per unit of time is relatively small and there is no excessive salivation. flow, so that ingestion of the active ingredient (with the disadvantages of gastrointestinal absorption mentioned) is largely excluded.
- the dosage forms according to the invention also increase compliance, since a special discipline is not required for the application.
- the application of the film-like dosage forms is generally not perceived as disruptive by the people to be treated due to the small layer thickness.
- the dosage forms according to the invention have a polymer matrix which serves as an active substance reservoir and has mucoadhesive properties. At least one layer or at least one surface of the dosage form has mucoadhesive properties.
- the dosage form can consist of a single layer or comprise several layers. In the case of a multilayer structure, at least one of the layers contains active substance.
- a dosage form is made up of a mucoadhesive, preferably single-layer polymer matrix, which contains one or more cannabis active ingredients.
- the active ingredient (s) can be present in the dosage form in dissolved, dispersed or emulsified form.
- the polymer matrix preferably contains one or more polymers which are water-soluble and / or swellable in aqueous media.
- the choice of such polymers can influence the mucoadhesive properties and the release behavior.
- Polymers from the following group are particularly suitable as water-soluble or swellable polymers: starch and starch derivatives, dextran; Cellulose derivatives, such as carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl ethyl cellulose, sodium carboxymethyl cellulose, ethyl or propyl cellulose;
- the polymer content is preferably 5 to 95 wt. -5s, particularly preferably 15 to 75 wt.%, Based on the dry matter of a dosage form.
- the dosage forms according to the invention contain a cannabis extract or a cannabis oil, preferably in a proportion of 0.5 to 50% by weight, particularly preferably in a proportion of 1 to 30
- the invention also encompasses dosage forms of the type mentioned which contain at least one cannabinoid active ingredient from the group consisting of tetrahydrocannabinol, cannabinol, cannabidiol and cannabichromes.
- Tetrahydrocannabinol in particular R- (6a, 10a) - ⁇ -9-tetrahydro-cannabinol, is particularly preferred as the active ingredient.
- the cannabinoid active ingredients can be of natural, semi-synthetic or synthetic origin.
- the active substance content is preferably 0.1 to 20% by weight, particularly preferably 0.5 to 10% by weight, based on the dry mass of a dosage form.
- a single presentation Form preferably contains 0.5 to 20 mg, particularly preferably 1 to 10 mg of active ingredient, e.g. B. Tetrahydrocannabinol.
- the dosage forms according to the invention can optionally contain one or more additives from the following groups: fillers, colorants, flavors, aromas, fragrances, emulsifiers, plasticizers, sweeteners, preservatives, permeation-promoting substances, pH regulators and antioxidants. Substances suitable for this are known in principle to the person skilled in the art.
- flavors, smells and aromas are particularly advantageous.
- the taste impression can be improved by adding a refreshing flavoring agent (eg menthol, eucalyptol).
- a refreshing flavoring agent eg menthol, eucalyptol.
- this enables the drug to be taken inconspicuously, since it smells like an ordinary refreshment candy. This also helps to improve compliance.
- the dosage forms according to the invention containing cannabis active ingredients are in film form, ie of thin and flat shape, for example in the form of thin platelets or small wafers (also referred to as “wafers”). These film-shaped platelets can have various geometrical shapes, for example circular, elliptical or elongated.
- the thickness is preferably 0.01 to 2 mm; it is particularly preferably in the range from 0.05 to 0.5 mm.
- the layer thickness should be as small as possible (preferably less than 0.2 mm).
- the dosage forms according to the invention can be constructed in two or more layers.
- the individual layers can differ with regard to one or more of the following parameters: polymer composition, active substance content, active substance concentration, content of additives.
- the dosage forms according to the invention containing cannabis active ingredients can advantageously be used in the treatment of diseases or symptoms of the disease, in particular in the case of: painful conditions in cancer and as a result of chemotherapy; Pain and wasting syndrome in AIDS; Nausea and vomiting, in particular nausea and vomiting as a side effect of chemotherapy, as well as in AIDS or hepatitis; Neuropathic pain; Anorexia or cachexia, particularly in the case of AIDS or advanced cancer; Symptoms of paralysis in multiple sclerosis or traumatic cross-sectional diseases; Dystonia movement disorders; Bronchial asthma; epileptic seizures or generalized epilepsy; Withdrawal symptoms of alcohol, benzodiazepine and opiate addiction; Parkinson disease; Dementia, especially Alzheimer's disease; Arthritis; Glaucoma; Migraine; Dysmenorrhea.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002489106A CA2489106A1 (en) | 2002-06-14 | 2003-05-08 | Film-shaped mucoadhesive administration form for administering cannabis active ingredients |
BR0311867-3A BR0311867A (pt) | 2002-06-14 | 2003-05-08 | Forma de ministração adesiva a mucosa em forma de pelìcula e uso de um extrato ou de um óleo de cannabis para a produção de uma forma de ministração adesiva a mucosa em forma de pelìcula |
US10/517,849 US20060039959A1 (en) | 2002-06-14 | 2003-05-08 | Film-Shaped Mucoadhesive Administration Forms For Administering Cannabis Agents |
AU2003227735A AU2003227735B2 (en) | 2002-06-14 | 2003-05-08 | Film-shaped mucoadhesive administration form for administering cannabis active ingredients |
EP03725174A EP1513494A2 (de) | 2002-06-14 | 2003-05-08 | Filmförmige mucoadhäsive darreichungsformen zur verabreichung von cannabis-wirkstoffen |
JP2004512706A JP4526384B2 (ja) | 2002-06-14 | 2003-05-08 | カンナビス活性成分の投与のためのフィルム型粘着性投与形態 |
IL16574404A IL165744A0 (en) | 2002-06-14 | 2004-12-13 | Film-shaped mucoadhesive administration forms for administration of cannabis agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10226494.5 | 2002-06-14 | ||
DE10226494A DE10226494A1 (de) | 2002-06-14 | 2002-06-14 | Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003105800A2 true WO2003105800A2 (de) | 2003-12-24 |
WO2003105800A3 WO2003105800A3 (de) | 2004-12-09 |
Family
ID=29719057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/004807 WO2003105800A2 (de) | 2002-06-14 | 2003-05-08 | Filmförmige mucoadhäsive darreichungsformen zur verabreichung von cannabis-wirkstoffen |
Country Status (11)
Country | Link |
---|---|
US (1) | US20060039959A1 (de) |
EP (1) | EP1513494A2 (de) |
JP (1) | JP4526384B2 (de) |
CN (1) | CN1658840A (de) |
AU (1) | AU2003227735B2 (de) |
BR (1) | BR0311867A (de) |
CA (1) | CA2489106A1 (de) |
DE (1) | DE10226494A1 (de) |
IL (1) | IL165744A0 (de) |
RU (1) | RU2324476C2 (de) |
WO (1) | WO2003105800A2 (de) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007083098A1 (en) * | 2006-01-18 | 2007-07-26 | Gw Pharma Limited | Cannabinoid-containing plant extracts as neuroprotective agents |
RU2503448C2 (ru) * | 2008-01-04 | 2014-01-10 | ДжиДаблЮ ФАРМА ЛИМИТЕД | Применение каннабиноидов в комбинации с антипсихотическим лекарственным средством |
US10092611B1 (en) | 2014-04-17 | 2018-10-09 | Cure Pharmaceutical Holding Corp. | Pharmaceutical composition and method of manufacturing |
WO2019034113A1 (zh) * | 2017-08-18 | 2019-02-21 | 汉义生物科技(北京)有限公司 | 预防和/或缓解痛经的大麻纤维及其在卫生用品中的应用 |
US10258580B2 (en) | 2011-07-01 | 2019-04-16 | Gw Pharma Limited | Cannabinoids for use in the treatment of neurodegenerative diseases or disorders |
WO2020030569A1 (fr) | 2018-08-10 | 2020-02-13 | Urgo Recherche Innovation Et Developpement | Composition filmogène mucoadhésive et son utilisation pour le traitement des douleurs liées aux poussées dentaires |
DE102019100483A1 (de) | 2019-01-10 | 2020-07-16 | Lts Lohmann Therapie-Systeme Ag | Oraler Dünnfilm |
US11344591B2 (en) | 2014-04-17 | 2022-05-31 | Cure Pharmaceutical Holding Corp. | Pharmaceutical composition and method of manufacturing |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
US8252328B2 (en) | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US9289583B2 (en) * | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US9066847B2 (en) * | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
US8357114B2 (en) | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
DE102006027791A1 (de) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | AchE-NMDA-Kombinationswafer |
US20070299687A1 (en) * | 2006-06-23 | 2007-12-27 | Pamela Palmer | Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed |
US8242178B2 (en) * | 2007-06-18 | 2012-08-14 | University Of South Carolina | Use of cannabidiol in the treatment of autoimmune hepatitis |
US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
JP5550717B2 (ja) | 2009-04-01 | 2014-07-16 | コルゲート・パーモリブ・カンパニー | メントール誘導体ならびに口腔活性剤および全身活性剤としてのそれらの使用 |
GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Gw伐瑪有限公司 | 使用植物大麻素次大麻二酚(cbdv)來治療癲癇之用途 |
WO2011147455A1 (en) * | 2010-05-27 | 2011-12-01 | Symrise Ag | Flavoring substance-included compounds |
RU2453559C1 (ru) | 2010-10-11 | 2012-06-20 | Общество С Ограниченной Ответственностью "Ниармедик Плюс" | Способ получения сополимера натрийкарбоксиметилцеллюлозы и госсипола и его применение в комплексной терапии пациентов с аутистическими расстройствами и когнитивными нарушениями |
GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
EP2968259B1 (de) | 2013-03-14 | 2022-09-14 | SC Laboratories Inc. | Bioaktive konzentrate und verwendungen davon |
CA2931486A1 (en) * | 2013-11-05 | 2015-05-14 | Ardent Llc | Sublingual cannabis dosage form and methods of making and using the same |
US10272038B2 (en) * | 2013-12-02 | 2019-04-30 | Intelgenx Corp. | Film dosage form with extended release mucoadhesive particles |
US11033493B2 (en) * | 2013-12-02 | 2021-06-15 | Intelgenx Corp. | Film dosage form with extended release mucoadhesive particles |
US9220294B2 (en) | 2014-02-11 | 2015-12-29 | Timothy McCullough | Methods and devices using cannabis vapors |
US10821240B2 (en) | 2014-02-11 | 2020-11-03 | Vapor Cartridge Technology Llc | Methods and drug delivery devices using cannabis |
US9380813B2 (en) | 2014-02-11 | 2016-07-05 | Timothy McCullough | Drug delivery system and method |
US10392178B2 (en) * | 2014-04-21 | 2019-08-27 | Zen Potion, Inc. | Preparing beverages containing cannabinoids using beverage containers with polymer matrices |
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
AU2015279612A1 (en) | 2014-06-27 | 2017-02-02 | Kenton L. Crowley | Buccal and sublingual cannabinoid formulations and method of making the same |
GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
WO2016092539A1 (en) * | 2014-12-07 | 2016-06-16 | One World Cannabis Ltd | Use of cannabis to treat migraine |
AU2015369710B2 (en) | 2014-12-23 | 2020-09-17 | Vertical Pharmaceuticals, Llc | Systems, devices and methods for dispensing oral transmucosal dosage forms |
US20160213027A1 (en) * | 2015-01-21 | 2016-07-28 | George Maniatakos | Pet food additive |
GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
US20160367491A1 (en) * | 2015-06-22 | 2016-12-22 | Johnson & Johnson Consumer Inc. | Method for providing a benefit to skin |
GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
US20170112188A1 (en) * | 2015-10-22 | 2017-04-27 | John Ostrander | Wrapper For Enclosing Smokable Substances |
US20170188616A1 (en) * | 2015-12-17 | 2017-07-06 | Therabis, Llc | Cannabinoid-enriched supplement |
GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
EP3538078A4 (de) * | 2016-11-11 | 2020-07-08 | Bennes, Inc. | Formulierungen zur effizienten verabreichung von cannabinoiden |
AU2017359973B2 (en) | 2016-11-15 | 2023-02-16 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
CN109498606A (zh) * | 2017-09-15 | 2019-03-22 | 汉义生物科技(北京)有限公司 | 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用 |
US20190125660A1 (en) * | 2017-10-31 | 2019-05-02 | Calitas Therapeutics, Inc | Orally dissolving mucoadhesive films utilizing menthol and l-arginine to enhance the bioavailability of cannabinoids |
GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
CN108743571B (zh) * | 2018-08-07 | 2020-10-02 | 云南汉木森生物科技有限责任公司 | 预防、治疗癫痫的药物组合物及其制备方法 |
US11602504B2 (en) * | 2018-11-05 | 2023-03-14 | Intelgenx Corp. | Lipophilic active oral film formulation and method of making the same |
CN110200953B (zh) * | 2019-06-15 | 2022-02-08 | 汉义生物科技(北京)有限公司 | 大麻素在制备吸入给药药物中的应用 |
CA3154135A1 (en) | 2019-09-16 | 2021-03-25 | Vapor Cartridge Technology Llc | Drug delivery system with stackable substrates |
EP3808341A1 (de) * | 2019-10-16 | 2021-04-21 | ADD Advanced Drug Delivery Technologies, Ltd. | Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen |
CN111150729B (zh) * | 2020-01-16 | 2021-02-12 | 全越 | 一种成膜组合物及其应用 |
CN111228241B (zh) * | 2020-01-16 | 2023-08-04 | 全越 | 一种成膜组合物及其应用 |
GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
US11986008B2 (en) | 2021-09-01 | 2024-05-21 | David Addington | Method of processing cannabis |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999015210A2 (en) * | 1997-09-26 | 1999-04-01 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
WO2000062764A1 (en) * | 1999-04-20 | 2000-10-26 | Alayne Yates | Gum pad for delivery of medication to mucosal tissues |
WO2001066089A2 (en) * | 2000-03-09 | 2001-09-13 | Gw Pharma Limited | Pharmaceutical compositions comprising cannabis |
WO2002064109A2 (en) * | 2001-02-14 | 2002-08-22 | Gw Pharma Limited | Mucoadhesive pharmaceutical formulations |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996000072A1 (en) * | 1994-06-23 | 1996-01-04 | The Procter & Gamble Company | Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine |
US6328992B1 (en) * | 1997-03-03 | 2001-12-11 | Lawrence L. Brooke | Cannabinoid patch and method for cannabis transdermal delivery |
US5989535A (en) * | 1997-08-15 | 1999-11-23 | Soma Technologies | Polymeric bioadhesive emulsions and suspensions and methods of treatment |
US6509005B1 (en) * | 1998-10-27 | 2003-01-21 | Virginia Commonwealth University | Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler |
DE10051427C1 (de) * | 2000-10-17 | 2002-06-13 | Adam Mueller | Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte |
US6730330B2 (en) * | 2001-02-14 | 2004-05-04 | Gw Pharma Limited | Pharmaceutical formulations |
US20030017216A1 (en) * | 2001-07-23 | 2003-01-23 | Schmidt Robert Gustav | Isolation of herbal and cannabinoid medicinal extracts |
EP1539069A4 (de) * | 2002-05-31 | 2007-11-14 | Univ Mississippi | Transmukosale abgabe von cannabinoiden |
-
2002
- 2002-06-14 DE DE10226494A patent/DE10226494A1/de not_active Withdrawn
-
2003
- 2003-05-08 JP JP2004512706A patent/JP4526384B2/ja not_active Expired - Fee Related
- 2003-05-08 RU RU2005100953/15A patent/RU2324476C2/ru not_active IP Right Cessation
- 2003-05-08 EP EP03725174A patent/EP1513494A2/de not_active Withdrawn
- 2003-05-08 WO PCT/EP2003/004807 patent/WO2003105800A2/de active Application Filing
- 2003-05-08 US US10/517,849 patent/US20060039959A1/en not_active Abandoned
- 2003-05-08 BR BR0311867-3A patent/BR0311867A/pt not_active IP Right Cessation
- 2003-05-08 AU AU2003227735A patent/AU2003227735B2/en not_active Ceased
- 2003-05-08 CN CN038137291A patent/CN1658840A/zh active Pending
- 2003-05-08 CA CA002489106A patent/CA2489106A1/en not_active Abandoned
-
2004
- 2004-12-13 IL IL16574404A patent/IL165744A0/xx unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999015210A2 (en) * | 1997-09-26 | 1999-04-01 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
WO2000062764A1 (en) * | 1999-04-20 | 2000-10-26 | Alayne Yates | Gum pad for delivery of medication to mucosal tissues |
WO2001066089A2 (en) * | 2000-03-09 | 2001-09-13 | Gw Pharma Limited | Pharmaceutical compositions comprising cannabis |
WO2002064109A2 (en) * | 2001-02-14 | 2002-08-22 | Gw Pharma Limited | Mucoadhesive pharmaceutical formulations |
Non-Patent Citations (2)
Title |
---|
GUY G W ET AL: "A PHASE ONE STUDY OF SUBLINGUAL CANNABIS-BASED MEDICINE EXTRACT" JOURNAL OF PHARMACY AND PHARMACOLOGY, LONDON, GB, Bd. 52, Nr. SUPPL, September 2000 (2000-09), Seite 294 XP000984304 ISSN: 0022-3573 * |
See also references of EP1513494A2 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2332533A1 (de) * | 2006-01-18 | 2011-06-15 | GW Pharma Limited | Pflanzliche Extrakte enthaltend Cannabinoide als Neuroprotectiva |
US8673368B2 (en) | 2006-01-18 | 2014-03-18 | Gw Pharma Limited | Cannabinoid-containing plant extracts as neuroprotective agents |
US9205063B2 (en) | 2006-01-18 | 2015-12-08 | Gw Pharma Limited | Cannabinoid-containing plant extracts as neuroprotective agents |
WO2007083098A1 (en) * | 2006-01-18 | 2007-07-26 | Gw Pharma Limited | Cannabinoid-containing plant extracts as neuroprotective agents |
RU2503448C2 (ru) * | 2008-01-04 | 2014-01-10 | ДжиДаблЮ ФАРМА ЛИМИТЕД | Применение каннабиноидов в комбинации с антипсихотическим лекарственным средством |
US10258580B2 (en) | 2011-07-01 | 2019-04-16 | Gw Pharma Limited | Cannabinoids for use in the treatment of neurodegenerative diseases or disorders |
US11344591B2 (en) | 2014-04-17 | 2022-05-31 | Cure Pharmaceutical Holding Corp. | Pharmaceutical composition and method of manufacturing |
US11844763B2 (en) | 2014-04-17 | 2023-12-19 | Avenir Wellness Solutions, Inc. | Pharmaceutical composition and method of manufacturing |
US11938160B2 (en) | 2014-04-17 | 2024-03-26 | Avenir Wellness Solutions, Inc. | Pharmaceutical composition and method of manufacturing |
US11266702B2 (en) | 2014-04-17 | 2022-03-08 | Cure Pharmaceutical Holding Corp. | Pharmaceutical composition and method of manufacturing |
US11890310B2 (en) | 2014-04-17 | 2024-02-06 | Avenir Wellness Solutions, Inc. | Pharmaceutical composition and method of manufacturing |
US11331358B2 (en) | 2014-04-17 | 2022-05-17 | Cure Pharmaceutical Holding Corp. | Pharmaceutical composition and method of manufacturing |
US10092611B1 (en) | 2014-04-17 | 2018-10-09 | Cure Pharmaceutical Holding Corp. | Pharmaceutical composition and method of manufacturing |
US11478520B2 (en) | 2014-04-17 | 2022-10-25 | Cure Pharmaceutical Holding Corp | Pharmaceutical composition and method of manufacturing |
WO2019034113A1 (zh) * | 2017-08-18 | 2019-02-21 | 汉义生物科技(北京)有限公司 | 预防和/或缓解痛经的大麻纤维及其在卫生用品中的应用 |
WO2020030569A1 (fr) | 2018-08-10 | 2020-02-13 | Urgo Recherche Innovation Et Developpement | Composition filmogène mucoadhésive et son utilisation pour le traitement des douleurs liées aux poussées dentaires |
FR3084837A1 (fr) | 2018-08-10 | 2020-02-14 | Urgo Recherche Innovation Et Developpement | Composition filmogene mucoadhesive et son utilisation pour le traitement des douleurs liees aux poussees dentaires |
DE102019100483A1 (de) | 2019-01-10 | 2020-07-16 | Lts Lohmann Therapie-Systeme Ag | Oraler Dünnfilm |
AU2020207004B2 (en) * | 2019-01-10 | 2023-02-02 | Lts Lohmann Therapie-Systeme Ag | Oral thin film |
US20220096367A1 (en) * | 2019-01-10 | 2022-03-31 | Lts Lohmann Therapie-Systeme Ag | Oral thin film |
WO2020144345A1 (de) | 2019-01-10 | 2020-07-16 | Lts Lohmann Therapie-Systeme Ag | Oraler dünnfilm |
Also Published As
Publication number | Publication date |
---|---|
CN1658840A (zh) | 2005-08-24 |
DE10226494A1 (de) | 2004-01-08 |
EP1513494A2 (de) | 2005-03-16 |
RU2005100953A (ru) | 2005-09-20 |
WO2003105800A3 (de) | 2004-12-09 |
JP2005533780A (ja) | 2005-11-10 |
CA2489106A1 (en) | 2003-12-24 |
US20060039959A1 (en) | 2006-02-23 |
IL165744A0 (en) | 2006-01-15 |
BR0311867A (pt) | 2005-03-15 |
RU2324476C2 (ru) | 2008-05-20 |
AU2003227735B2 (en) | 2009-07-09 |
AU2003227735A1 (en) | 2003-12-31 |
JP4526384B2 (ja) | 2010-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003105800A2 (de) | Filmförmige mucoadhäsive darreichungsformen zur verabreichung von cannabis-wirkstoffen | |
US11938160B2 (en) | Pharmaceutical composition and method of manufacturing | |
US11844763B2 (en) | Pharmaceutical composition and method of manufacturing | |
EP0125634B1 (de) | Verwendung einer sekretolytisch wirkenden Substanz zur Herstellung eines Antischnarchmittels und zur Bekämpfung des Schnarchphänomens | |
DE102006027794A1 (de) | Antihypertonie-Kombinationswafer | |
WO2020234650A1 (en) | Pharmaceutical compositions comprising cbd and terpene compositions | |
Santos et al. | Mast cell involvement in the rat paw oedema response to 1, 8-cineole, the main constituent of eucalyptus and rosemary oils | |
EP1638521A1 (de) | Transmukosale darreichungsform mit vreminderter schleimhautirritation | |
EP2029097A2 (de) | Antidepressiva-kombinations-wafer | |
CH662734A5 (de) | Antischnarchmittel. | |
WO2007144085A1 (de) | Opioid-kombinations-wafer | |
EP1656112B1 (de) | Buccale formulierungen des galanthamins und deren anwendungen | |
WO2007144081A2 (de) | Raucherentwöhnungs-kombinationswafer | |
DE10354894A1 (de) | Orale Formulierungen des Desoxypeganins und deren Anwendungen | |
KR20050021003A (ko) | 대마 활성 성분의 투여용 필름 형상의 점막접착성 투여 제형 | |
EP1383503B1 (de) | Verwendung von desoxypeganin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen | |
DE10301930A1 (de) | Verfahren zur medikamentösen therapeutischen oder prophylaktischen Behandlung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BR CA CN IL IN JP KR MX NZ PH PL RU US ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2489106 Country of ref document: CA Ref document number: 2003725174 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038137291 Country of ref document: CN Ref document number: 3953/DELNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004512706 Country of ref document: JP Ref document number: 1020047020346 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003227735 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2005100953 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047020346 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003725174 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006039959 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10517849 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10517849 Country of ref document: US |